Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 3 monotherapy (NCT04504370)

Phase 3 monotherapy (NCT04504370)

PB-119 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
PB-119
Population
t2d
Official title
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Sponsor
PegBio Co., Ltd.
Phase
3
Registry status
completed · 2020-04 → 2022-03
Participants
273
Duration
24 weeks
Registry
NCT04504370

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
150 μg QWt2d china24137——−1.4 vs −0.62.24.4 vs 7.48.0 vs 0.75.8 vs 0.06.6 vs 1.5—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (6)
  • 150 μg QW · hba1c · publication
    the least squares mean (LSM) change from baseline in HbA1c was −1.36% (95% CI 1.52 to −1.20)
  • 150 μg QW · nausea · Table 4 (safety set; double-blind 24-week period; Visepegena
    Nausea 11 (8.0) 32 1 (0.7)
  • 150 μg QW · vomiting · Table 4 (safety set; double-blind 24-week period; Visepegena
    Vomiting 8 (5.8) 14 0 (0.0)
  • 150 μg QW · ae_dc · publication
    The common cause of treatment discontinuation was AE in three (2.2%) participants of the visepegenatide group
  • 150 μg QW · disc_any · publication
    Six (4.4%) participants received visepegenatide and 10 (7.4%) participants received placebo discontinued the treatment in the double-blinded treatment period.
  • 150 μg QW · sae · Table 4 (safety set; double-blind 24-week period; Visepegena
    Serious Adverse Events (SAEs) 9 (6.6) 10 2 (1.5)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 3 monotherapy (NCT04504370). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-monotherapy/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.